All news

Viking Therapeutics stock faces dilution after USD 575.0 million raise

Alpha Vantage · AD HOC NEWS · · AI-summarised by FinFlash

Viking Therapeutics completed a $575.0 million stock and convertible-note offering that closed on September 28, 2026, to fund its pipeline including VK2735 and VK3019. The financing diluted existing shareholders, and shares are trading below the offering price. Analysts maintain a bullish stance, with 18 buy ratings, 2 holds and no sells, and an average price target of $94.82 versus a $29.94 share price.

Read original source

VKTX company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.